NEW PERSPECTIVES OF PERSONALIZED THERAPY OF CHRONIC HEPATITIS C



如何引用文章

全文:

详细

The aim of this review - to analyze the possibilities of traditional therapy and opening new perspectives and approaches to personalized theraру of patients with chronic viral hepatitis C. There are considered the viral and patien tfactors that have an mpact on the efficacy of theтру with interferon-a2 and ribavirin. There are presented data on the molecular mechanism of action of these drugs preparations. There are considered new antiviral drugs (protease inhibitors) and pharmacological agents being under development and targeted to viral polymerase andprotein NS5A.

全文:

Новые перспективы персонифицированной терапии хронического вирусного гепатита с
×

作者简介

G. Sapronov

Russian Medical Academy of Post-Graduate Education

Email: geo8@inbox.ru
2/1, Barrikadnaya Str., Moscow, Russian Federation, 123836

L. Nikolaeva

Ivanovsky Institute of Virology

Email: L.i.nikolaeva@mail.ru
16, Gamaleya Str., Moscow, Russian Federation, 123098

参考

  1. Гайдаренко А.Д. Прогнозирование проявлений эпидемиологического процесса гепатита С на основе компьютерного моделирования. Автореф. дис.. канд. биол. наук. М.; 2009.
  2. Robbins P.S., Myers G., Howard C. et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on virus taxonomy. Arch. Virol. 1998; 143: 24932503.
  3. Choo Q.-L., Kuo G., Wiener A.L. et al. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
  4. Yu X, Qiao M, Atanasov I. et al. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology. 2007; 367: 126-34.
  5. Nielsen S.U., Bassendine M.F., Martin C. et al. Characterization of hepatitis C RNA-containing particles from human liver by density and size. J. Gen. Virol. 2008; 89: 2507-17.
  6. Gastaminza P., Dryden K.A., Boyd B. et al. Ultrastructural and biophysical characterization of hepatitis C virus particles, pro duced in cell culture. J. Virol. 2010; 84: 10999-11009.
  7. Simmonds P., Bukh J., Combet C. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. J. Hepatol. 2005; 42: 962-73.
  8. Бурневич Э. Уроки IDEAL. Врач. 2008; Специальный выпуск: 1-20.
  9. Nelson D.R., Davis G.L., Jacobson I. et al. Вирусный гепатит С: критическая оценка подходов к лечению. Клиническая гастроэнтерология и гепатология (русское изд.). 2009; 2: 33957.
  10. Poynard T., McHutchison, Goodman Z. et al. (for the ALGOVIRC Project Group). Is an «a la carte» combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. 2000; 31: 211-18.
  11. Соринсон С.Н. В кн.: Вирусные гепатиты. СПб.: Теза; 1998: 201
  12. Chevaliez S., Pawlotsky J.M. Interferon-based therapy of hepatitis C. Adv. Drug Deliv. Rev. 2007; 59: 1222-41.
  13. Huang Z., Murray M.G., Secrist J.A. Recent development of therapeutics for chronic HCV infection. Antiviral res. 2006; 71: 351-62.
  14. Pawlotsky J.M., Dahari H., Neumann A.U. et al. Antiviral action of ribavirin in chronic hepatirtis C. Gastroenterology. 2004; 126: 703 14.
  15. Hezode C., Forestier N., Dusheiko G. et al. Telaprevir and peginter-feron with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009; 360: 1839-50.
  16. Hofmann W.P., Herrmann E., Sarrazin C. et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 2008; 28: 1332-43.
  17. Gish R.G., Arora S., Rajender Reddy K. et al. Virilogical response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegy-lated interferon alfa-2a: randomized, phase 2 study. J. Hepatology. 2007; 47: 51-9.
  18. Hadziyanns S.J., Sette H. Jr., Morgan T.R. et al. Peginterferon-al-pha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-55.
  19. Roulot D., Bourcier V., Grando V. et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J. Viral. Hepatol. 2007; 14: 460-7.
  20. Enomoto N., Sakuma I., Asahira Y. et al. Comparision of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 1995; 96: 224-30.
  21. Brillet R., Penin F., Hezode C. et al. The nonstructural 5A protein of hepatitis c virus genotype 1b does not contain an interferon sensitiv-ity-determination region. J. Infect. Dis. 2007; 195: 432-41.
  22. Yuan H.J., Jain M., Snow K.K. et al. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribabirin therapy. J. Viral. Hepatol. 2010; 17: 208-16.
  23. Jardim A.C., Yamasaki L.H., de Queiróz A.T. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin. Infect. Genet. Evol. 2009; 9: 689-98.
  24. Munoz de Rueda P., Casado J., Paton R. et al. Mutation in E2-PeRHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferonribavirin therapy responses. J. Virol. 2008; 82: 6644-53.
  25. Akuta N., Suzuki F., Sezaki H. et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005; 48: 372-80.
  26. Akuta N., Suzuki F., Hirakawa M. et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained viro-logical response. J. Med. Virol. 2009; 81: 452-8.
  27. Alestig E., Arnholm B., Eilard A. et al. Core mutations, IL-28B poly-morfisms and respose to peginterferon/ribavirin treatment in Swedish patients infected with hepatitis C virus genotype 1 infection. BMC Infect. Dis. 2011; 11: 124-30.
  28. Taylor D.R., Shi S.T., Romano PR. et al. Inhibition of the interferon-inducible protein kinase PRK by HCV E2 protein. Science. 1999; 285: 107-10.
  29. Boicic F., Sede M., Moretti F et al. Ananlysis of the PKR-eIF2alpha phosphorilation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Arch. Virol. 2012; 157: 703-11.
  30. Noguchi T., Otsubaki T., Ando I. et al. Isolation and gene analysis of interferon alpha-resistant cell clones of the hepatitis C virus subgenome. Virology. 2008; 375: 424-32.
  31. Chevalies S., Asselah T. Mechanism of non-response to antiviral treatment in chronic hepatitis C. Clin. Res. Hepatol. Gastroenterol. 2011; 55: S31-41.
  32. Николаева Л.И., Макашова В.В., Петрова Е.В. и др. Снижение содержания антител к вирусу гепатита С при антивирусной терапии. Биомедицинская химия. 2009; 55: 201-12.
  33. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401.
  34. Suppiah V, Moldovan M., Ahlensiel G. et al. IL-28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genet. 2009; 41: 1100-4.
  35. Tanaka Y., Nishida N., Sugiyama M. et al. Genome-wide association with response to pegylated inetrferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-9.
  36. Thomas D.L., Thio C.L., Martin M.P. et al. Genetic variation in IL-28B and spontanepus clearance of hepatitis C virus. Nature. 2009; 461: 798-801.
  37. Sarasin-Filipowics M., Oakeley E.J., Duong FH. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Prec. Natl. Asad. Sci (USA). 2008; 105: 7034-9.
  38. Asselah T., Bieche I., Bedossa P. et al. Gene expression and hepatitis C virus infection. Gut. 2009; 58: 846-58.
  39. McGilvray I., Feld J.J., Chen L. et al. Hepatic cell-specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology. 2012; 142: 1122-31.
  40. Butera D., Marukian S., Iwamaye A.E. et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005; 106: 1175-82.
  41. Ji X., Cheung R., Cooper S. et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology. 2003; 37: 610-21.
  42. Casrouge A., Decalf J., Ahloulay M. et al. Evidance for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 2011; 121: 308-17.
  43. Lagging M., Askarieh G., Negro F et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE. 2011; 6: e17232.
  44. Hinrichsen H., Benhamou Y., Wedemeyer H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterol. 2004; 127: 1347-55.
  45. Pawlotsky J.M. The results of phase III clinical trial with telaprevir and boceprevir presented at The Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology. 2011; 140: 746-54.
  46. Silva M., Kasserra C., Gupta S. et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Hepatol. Int. 2011; 5: 355-8.
  47. Sanchez-Tapias J.M. Treatment of HCV genotype 1 naive patients with triple therapy: who, when and how long. Giner P., Forns X., Abraldes J.G., eds. In: Therapy liver diseases. Barcelona: Elsevier Doyma; 2011: 23-2.
  48. KwoP.Y., VinayekR. The therapeutic approaches for hepatitis c virus: protease inhibitors and polymerase inhibitors. Gut Liver. 2011; 5: 406-17.
  49. Bartels D.J., Zhou Y., Zhang E.Z. et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 2008; 198: 800-7.
  50. Robinson M., Tian Y., Delaney W.E. et al. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Prec. Natl Acad. Sci. (USA). 2011; 108: 10290-5.
  51. Bressanelli S., Tomei L., Roussel A., et al. Crystal structure of RNA-dependent RNA polymerase of hepatitis C virus. Prec. Natl Acad. Sci (USA). 1999; 96: 13034-9.
  52. Guedi J.,Dahari H., Shudo E. et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepa-tology. 2011; 55: 1030-7.
  53. Lalezari J., Gane E., Rodriguez-Torres M. et al. Potent antivaral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days. J. Hepatol. 2008; 48 (Suppl. 2): S29.
  54. Gane E.J., Roberts S.K., Stedman C.A. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010; 376: 1467-75.
  55. Brainard D.M., Anderson M.S., Petry A. et al. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281, in treatment-naive genotype 1a, 1b and 3 HCV-infected patients. Hepatology. 2009; 50 (Suppl. 4): 263A.
  56. Rodriguez-Torres M., Lawitz E., Conway B. et al. Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 treatment-naive genotype 1 HCV-infected patients. J. Hepatol. 2010; 52 (Suppl. 1): S14.
  57. Lawitz E., Rodriguez-Torres M., Rustgi V.K. et al. Safety and antiviral activity of ANA-598 in combination with pegylated interferon alpha2a plus ribavirin in treatment-naive genotype 1 chronic HCV patients. J. Hepatol. 2010; 52 (Suppl. 1): S467.
  58. Shih I., Vliegen I., Peng B. et al. Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of HCV NS5B polymerase. Antimicrob. Agents Chemother. 2011; 55: 4196-203.
  59. Gao M., Nettles R.E., Belema M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010; 465: 96-100.
  60. Nettles R., Chien C., Chung E. et al. BMS-790052 is a first-in-class potent hepatitis C (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology. 2008; 48 (Suppl. 1): 1025A.
  61. Lawitz E.J., Gruener D., Hill J.M. et al. A phase 1, randomized, placebo-controlled, three-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J. Hepatol. 2012; 57: 24-31.
  62. Ghany M.G. Nelson D.R., Strader D.B. et al. An update on trea-ment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-44.
  63. Casey L.C., Lee W.M. Hepatitis C virus therapy update 2013. Curr. Opin. Gastroenterol. 2013; 29: 243-9.
  64. Kanda T., Yokosuka D., Omada M. Treatment of hepatitis C virus infection in future. Clinical and Translational Medicine. 2013; 2: www. clintransmed.com/ content/2/1/9.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-vector, 2013


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 014448 от 08.02.1996. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80652 от 15.03.2021 .


##common.cookie##